Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
Abstract Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell products have been approved by the US Food and Drug Administration (FDA). Nevertheless, some significant toxicities po...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
BMC
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/84985de6e1064d9e8565a628289e86e7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:84985de6e1064d9e8565a628289e86e7 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:84985de6e1064d9e8565a628289e86e72021-11-21T12:13:09ZMechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies10.1186/s13046-021-02148-61756-9966https://doaj.org/article/84985de6e1064d9e8565a628289e86e72021-11-01T00:00:00Zhttps://doi.org/10.1186/s13046-021-02148-6https://doaj.org/toc/1756-9966Abstract Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell products have been approved by the US Food and Drug Administration (FDA). Nevertheless, some significant toxicities pose great challenges to the development of CAR T-cell therapy, most notably cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Understanding the mechanisms underlying these toxicities and establishing prevention and treatment strategies are important. In this review, we summarize the mechanisms underlying CRS and ICANS and provide potential treatment and prevention strategies.Xinyi XiaoShengkang HuangSifei ChenYazhuo WangQihang SunXinjie XuYuhua LiBMCarticleCAR T-cellCytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)NeurotoxicityMechanismsManagementNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-23 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
CAR T-cell Cytokine release syndrome (CRS) Immune effector cell-associated neurotoxicity syndrome (ICANS) Neurotoxicity Mechanisms Management Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
CAR T-cell Cytokine release syndrome (CRS) Immune effector cell-associated neurotoxicity syndrome (ICANS) Neurotoxicity Mechanisms Management Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Xinyi Xiao Shengkang Huang Sifei Chen Yazhuo Wang Qihang Sun Xinjie Xu Yuhua Li Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies |
| description |
Abstract Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell products have been approved by the US Food and Drug Administration (FDA). Nevertheless, some significant toxicities pose great challenges to the development of CAR T-cell therapy, most notably cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Understanding the mechanisms underlying these toxicities and establishing prevention and treatment strategies are important. In this review, we summarize the mechanisms underlying CRS and ICANS and provide potential treatment and prevention strategies. |
| format |
article |
| author |
Xinyi Xiao Shengkang Huang Sifei Chen Yazhuo Wang Qihang Sun Xinjie Xu Yuhua Li |
| author_facet |
Xinyi Xiao Shengkang Huang Sifei Chen Yazhuo Wang Qihang Sun Xinjie Xu Yuhua Li |
| author_sort |
Xinyi Xiao |
| title |
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies |
| title_short |
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies |
| title_full |
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies |
| title_fullStr |
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies |
| title_full_unstemmed |
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies |
| title_sort |
mechanisms of cytokine release syndrome and neurotoxicity of car t-cell therapy and associated prevention and management strategies |
| publisher |
BMC |
| publishDate |
2021 |
| url |
https://doaj.org/article/84985de6e1064d9e8565a628289e86e7 |
| work_keys_str_mv |
AT xinyixiao mechanismsofcytokinereleasesyndromeandneurotoxicityofcartcelltherapyandassociatedpreventionandmanagementstrategies AT shengkanghuang mechanismsofcytokinereleasesyndromeandneurotoxicityofcartcelltherapyandassociatedpreventionandmanagementstrategies AT sifeichen mechanismsofcytokinereleasesyndromeandneurotoxicityofcartcelltherapyandassociatedpreventionandmanagementstrategies AT yazhuowang mechanismsofcytokinereleasesyndromeandneurotoxicityofcartcelltherapyandassociatedpreventionandmanagementstrategies AT qihangsun mechanismsofcytokinereleasesyndromeandneurotoxicityofcartcelltherapyandassociatedpreventionandmanagementstrategies AT xinjiexu mechanismsofcytokinereleasesyndromeandneurotoxicityofcartcelltherapyandassociatedpreventionandmanagementstrategies AT yuhuali mechanismsofcytokinereleasesyndromeandneurotoxicityofcartcelltherapyandassociatedpreventionandmanagementstrategies |
| _version_ |
1718419134200414208 |